Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 59Leukemia 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Gastrointestinal Stromal Tumors 12Leukemia, Myeloid, Chronic-Phase 11Neoplasms 5Blast Crisis 4Recurrence 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Philadelphia Chromosome 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Sarcoma 1Piebaldism 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Neurofibromatoses 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplastic Processes 1Myeloproliferative Disorders 1Mucosal Lentiginous Melanoma 1Mastocytosis, Systemic 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1

Interventions

pexidartinib 3nilotinib 1cabiralizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Giant Cell Tumor of Tendon Sheath × nilotinib × Clear all
NCT01207492 2026-02-20

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Dana-Farber Cancer Institute

Phase 2 Completed
17 enrolled 8 charts

Giant Cell Tumor of Tendon Sheath, Synovitis, Pigmented Villonodular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡